Thursday, June 26, 2025
Opus Genetics VEGA-3 Phase 3 Trial Meets Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for Presbyopia
The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieving a ≥15-letter improvement in binocular DCNVA, with less than a 5-letter loss in binocular BCDVA at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (p<0.0001).